POXEL — Poxel SA Share News
0.000.00%
Last trade - 00:00- €9.32m
- €68.25m
- €6.64m
Brief: Poxel Reports H1 Financial Loss Of 1.2 Million Euros
Brief: Poxel Finalized Recruitment In Phase II Study Of PXL065
Brief: Poxel H1 Revenue At EUR 13.3 MLN
Brief: Poxel Announces New Strategic Direction
Brief: Poxel: latest clinical studies backed efficacy for its PXL770 product
Brief: Poxel And Sumitomo Dainippon Pharma Announce Approval Of Twymeeg® For Treatment Of Type 2 Diabetes In Japan
Brief: Poxel To Participate To Mitochondria-Targetted Drug Development Summit
Brief: Poxel Reports No Revenue For Q1 2021
Brief: Poxel FY Revenue Down At EUR 6.8 Million
Brief: Poxel End-Dec Total Cash And Cash Equivalents At EUR 40.2 Million
Brief: Poxel Regains Imeglimin Rights From Metavant
Brief: Poxel: More Positive Phase 2A Results, Phase 2B Plan For Pxl770 In NASH
Brief: Poxel Says Metavant Decided Not To Advance Imeglimin Into Phase 3 Program
Brief: Poxel Presents Phase 1B Clinical Results For PXl065 And New Preclinical Data For PXL770
Brief: Poxel 9-Month Revenue Down At 6.6 Million Euros
Brief: Poxel Secures EUR 6 Million In Non-Dilutive Financing Guaranteed By French Government
Europe Research Roundup: Deutsche Bank, Lonza Group, William Hill
Brief: Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770
Brief: Poxel To Present Imeglimin Phase 3 Results For TIMES 2 and TIMES 3 And New Results For PXL770 At 56th EASD Annual Meeting